IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations
VCs Consider Risk, Have Not Shifted Investment Strategies
Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.
You may also be interested in...
Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.